Review





Similar Products

93
Sino Biological recombinant lgals9
Recombinant Lgals9, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Human+Galectin-9+%2F+LGALS9+Protein/pm41437376-123-20-23
Average 93 stars, based on 1 article reviews
recombinant lgals9 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems human gal9 protein
Human Gal9 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Recombinant+Human+Galectin-9+Protein%2C+CF/us12497458-1444-19-22
Average 93 stars, based on 1 article reviews
human gal9 protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems galectin 9 knockdown dcs
Galectin 9 Knockdown Dcs, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Recombinant+Human+Galectin-9+Protein%2C+CF/pm41359845-289-2-16
Average 93 stars, based on 1 article reviews
galectin 9 knockdown dcs - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems recombinant galectin 9 protein
Recombinant Galectin 9 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Human+Galectin-9+Antibody/pmc12456409-202-6-10
Average 94 stars, based on 1 article reviews
recombinant galectin 9 protein - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
R&D Systems human gal 9 protein
Human Gal 9 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Recombinant+Human+Galectin-9+Protein%2C+CF/bio_rxiv__2025__07__31__666261-48-17-20
Average 93 stars, based on 1 article reviews
human gal 9 protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems protein
Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Recombinant+Human+Galectin-9+Protein%2C+CF/bio_rxiv__2025__07__31__666261-222-3-7
Average 93 stars, based on 1 article reviews
protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems lgals9 protein
( A ) Violin plots showing upregulation of IFN-inducible genes IFITM2 and IFITM3 in LECs from rejecting allografts. ( B ) UMAP of the scRNA-Seq data showing enrichment of IFN-γ within the T/NK cell cluster. ( C ) UMAP showing enrichment of an IFN-γ signature, including IFNGR1 , IFNGR2 , IFITM2 , and IFITM3 . ( D ) CellPhoneDB interaction map depicting predicted lymphatic-CD4 + T cell crosstalk in rejection. Inhibitory interactions (blue) include PVR and <t>LGALS9;</t> stimulatory interactions (red) are also shown. Node size reflects expression frequency; line intensity indicates interaction strength. Ligands of interest, PVR and LGALS9 , are highlighted. ( E ) Heatmap of immune checkpoint interactions between LECs and effector CD4 + T cells across disease states. Color indicates normalized CellPhoneDB interaction score. All scores were normalized for each ligand-receptor pair. ( F ) Immunofluorescence validation of PVR expression on PDPN + lymphatics (arrowhead) in rejecting kidneys ( n = 2); CD4 + T cell shown in contact (asterisk). Scale bar: 30 μm. ( G ) IFN-γ stimulation of cultured human LECs increases LGALS9 levels at 24 and 48 hours (qPCR; *** P = 0.0002, ** P = 0.0093, respectively) relative to HPRT. ( H ) LGALS9 protein secretion increased at 48 and 72 hours (ELISA; *** P = 0.0002, **** P < 0.0001, respectively) after IFN-γ stimulation of cultured human LECs. qPCR and ELISA experiments were repeated 3 times, and all assays were performed in duplicate, with each dot on the graph representing the mean data obtained for each repeat.
Lgals9 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Recombinant+Human+Galectin-9+Protein%2C+CF/pmc12435838-182-1-10
Average 93 stars, based on 1 article reviews
lgals9 protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems recombinant human lgals9 protein
Cell–cell communication analysis reveals <t>LGALS9–P4HB</t> as a key interaction between myeloid and epithelial cells in metastatic sites. (A) Heatmap showing total cell interactions in liver metastases. (B) Heatmap showing total cell interactions in lymph node metastases. (C) Outgoing and incoming signalling patterns in liver metastases. (D) Outgoing and incoming signalling patterns in lymph node metastases. (E) Dot plot showing ligand–receptor pairs mediating immune cell–epithelial cell communication in liver metastases. (F) Dot plot showing ligand–receptor pairs mediating immune cell–epithelial cell communication in lymph node metastases. (G) Network diagram of cellular interactions in liver metastases. (H) Network diagram of cellular interactions in lymph node metastases. (I) Violin plots showing expression of LGALS9 and its receptors (P4HB, HAVCR2, CD44) across different cell types in liver metastases. (J) Violin plots showing expression of LGALS9 and its receptors across different cell types in lymph node metastases.
Recombinant Human Lgals9 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+galectin-9+protein/Recombinant+Human+Galectin-9+Protein%2C+CF/pmc12176694-51-0-4
Average 93 stars, based on 1 article reviews
recombinant human lgals9 protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


( A ) Violin plots showing upregulation of IFN-inducible genes IFITM2 and IFITM3 in LECs from rejecting allografts. ( B ) UMAP of the scRNA-Seq data showing enrichment of IFN-γ within the T/NK cell cluster. ( C ) UMAP showing enrichment of an IFN-γ signature, including IFNGR1 , IFNGR2 , IFITM2 , and IFITM3 . ( D ) CellPhoneDB interaction map depicting predicted lymphatic-CD4 + T cell crosstalk in rejection. Inhibitory interactions (blue) include PVR and LGALS9; stimulatory interactions (red) are also shown. Node size reflects expression frequency; line intensity indicates interaction strength. Ligands of interest, PVR and LGALS9 , are highlighted. ( E ) Heatmap of immune checkpoint interactions between LECs and effector CD4 + T cells across disease states. Color indicates normalized CellPhoneDB interaction score. All scores were normalized for each ligand-receptor pair. ( F ) Immunofluorescence validation of PVR expression on PDPN + lymphatics (arrowhead) in rejecting kidneys ( n = 2); CD4 + T cell shown in contact (asterisk). Scale bar: 30 μm. ( G ) IFN-γ stimulation of cultured human LECs increases LGALS9 levels at 24 and 48 hours (qPCR; *** P = 0.0002, ** P = 0.0093, respectively) relative to HPRT. ( H ) LGALS9 protein secretion increased at 48 and 72 hours (ELISA; *** P = 0.0002, **** P < 0.0001, respectively) after IFN-γ stimulation of cultured human LECs. qPCR and ELISA experiments were repeated 3 times, and all assays were performed in duplicate, with each dot on the graph representing the mean data obtained for each repeat.

Journal: The Journal of Clinical Investigation

Article Title: Organ-specific features of human kidney lymphatics are disrupted in chronic transplant rejection

doi: 10.1172/JCI168962

Figure Lengend Snippet: ( A ) Violin plots showing upregulation of IFN-inducible genes IFITM2 and IFITM3 in LECs from rejecting allografts. ( B ) UMAP of the scRNA-Seq data showing enrichment of IFN-γ within the T/NK cell cluster. ( C ) UMAP showing enrichment of an IFN-γ signature, including IFNGR1 , IFNGR2 , IFITM2 , and IFITM3 . ( D ) CellPhoneDB interaction map depicting predicted lymphatic-CD4 + T cell crosstalk in rejection. Inhibitory interactions (blue) include PVR and LGALS9; stimulatory interactions (red) are also shown. Node size reflects expression frequency; line intensity indicates interaction strength. Ligands of interest, PVR and LGALS9 , are highlighted. ( E ) Heatmap of immune checkpoint interactions between LECs and effector CD4 + T cells across disease states. Color indicates normalized CellPhoneDB interaction score. All scores were normalized for each ligand-receptor pair. ( F ) Immunofluorescence validation of PVR expression on PDPN + lymphatics (arrowhead) in rejecting kidneys ( n = 2); CD4 + T cell shown in contact (asterisk). Scale bar: 30 μm. ( G ) IFN-γ stimulation of cultured human LECs increases LGALS9 levels at 24 and 48 hours (qPCR; *** P = 0.0002, ** P = 0.0093, respectively) relative to HPRT. ( H ) LGALS9 protein secretion increased at 48 and 72 hours (ELISA; *** P = 0.0002, **** P < 0.0001, respectively) after IFN-γ stimulation of cultured human LECs. qPCR and ELISA experiments were repeated 3 times, and all assays were performed in duplicate, with each dot on the graph representing the mean data obtained for each repeat.

Article Snippet: Secreted LGALS9 protein in conditioned media was measured by ELISA (R&D Systems).

Techniques: Expressing, Immunofluorescence, Biomarker Discovery, Cell Culture, Enzyme-linked Immunosorbent Assay

Cell–cell communication analysis reveals LGALS9–P4HB as a key interaction between myeloid and epithelial cells in metastatic sites. (A) Heatmap showing total cell interactions in liver metastases. (B) Heatmap showing total cell interactions in lymph node metastases. (C) Outgoing and incoming signalling patterns in liver metastases. (D) Outgoing and incoming signalling patterns in lymph node metastases. (E) Dot plot showing ligand–receptor pairs mediating immune cell–epithelial cell communication in liver metastases. (F) Dot plot showing ligand–receptor pairs mediating immune cell–epithelial cell communication in lymph node metastases. (G) Network diagram of cellular interactions in liver metastases. (H) Network diagram of cellular interactions in lymph node metastases. (I) Violin plots showing expression of LGALS9 and its receptors (P4HB, HAVCR2, CD44) across different cell types in liver metastases. (J) Violin plots showing expression of LGALS9 and its receptors across different cell types in lymph node metastases.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Myeloid‐Derived LGALS9 ‐ P4HB Immune Interaction Promotes Metastasis in Gastric Cancer Through Enhanced Cell Proliferation and Lipid Metabolism

doi: 10.1111/jcmm.70661

Figure Lengend Snippet: Cell–cell communication analysis reveals LGALS9–P4HB as a key interaction between myeloid and epithelial cells in metastatic sites. (A) Heatmap showing total cell interactions in liver metastases. (B) Heatmap showing total cell interactions in lymph node metastases. (C) Outgoing and incoming signalling patterns in liver metastases. (D) Outgoing and incoming signalling patterns in lymph node metastases. (E) Dot plot showing ligand–receptor pairs mediating immune cell–epithelial cell communication in liver metastases. (F) Dot plot showing ligand–receptor pairs mediating immune cell–epithelial cell communication in lymph node metastases. (G) Network diagram of cellular interactions in liver metastases. (H) Network diagram of cellular interactions in lymph node metastases. (I) Violin plots showing expression of LGALS9 and its receptors (P4HB, HAVCR2, CD44) across different cell types in liver metastases. (J) Violin plots showing expression of LGALS9 and its receptors across different cell types in lymph node metastases.

Article Snippet: Recombinant human LGALS9 protein (R&D Systems) was added to the culture medium at a concentration of 150 ng/mL.

Techniques: Expressing

LGALS9 activates P4HB to promote gastric cancer cell proliferation, EMT and lipid metabolism. (A) Relative expression of P4HB in different gastric cell lines measured by qRT‐PCR. (B) Expression of proliferation‐related genes (Ki‐67, PCNA, Cyclin D1) in MKN‐74 cells treated with recombinant LGALS9 or LGALS9 conditional medium, determined by qRT‐PCR. (C) Cell viability of MKN‐74 cells treated with recombinant LGALS9 over time, measured by MTT assay. (D) Cell viability of MKN‐74 cells cultured in LGALS9 conditional medium over time. (E) EdU incorporation assay showing proliferation of MKN‐74 cells treated with recombinant LGALS9. (F) EdU incorporation assay showing proliferation of MKN‐74 cells cultured in LGALS9 conditional medium. (G) Western blot analysis of EMT markers (E‐cadherin, N‐cadherin, Vimentin) in MKN‐74 cells with indicated treatments. (H) qRT‐PCR analysis of lipid metabolism–related genes in MKN‐74 cells treated with LGALS9 conditional medium (upper panel) or recombinant LGALS9 (lower panel). Statistical significance is indicated by asterisks: * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Myeloid‐Derived LGALS9 ‐ P4HB Immune Interaction Promotes Metastasis in Gastric Cancer Through Enhanced Cell Proliferation and Lipid Metabolism

doi: 10.1111/jcmm.70661

Figure Lengend Snippet: LGALS9 activates P4HB to promote gastric cancer cell proliferation, EMT and lipid metabolism. (A) Relative expression of P4HB in different gastric cell lines measured by qRT‐PCR. (B) Expression of proliferation‐related genes (Ki‐67, PCNA, Cyclin D1) in MKN‐74 cells treated with recombinant LGALS9 or LGALS9 conditional medium, determined by qRT‐PCR. (C) Cell viability of MKN‐74 cells treated with recombinant LGALS9 over time, measured by MTT assay. (D) Cell viability of MKN‐74 cells cultured in LGALS9 conditional medium over time. (E) EdU incorporation assay showing proliferation of MKN‐74 cells treated with recombinant LGALS9. (F) EdU incorporation assay showing proliferation of MKN‐74 cells cultured in LGALS9 conditional medium. (G) Western blot analysis of EMT markers (E‐cadherin, N‐cadherin, Vimentin) in MKN‐74 cells with indicated treatments. (H) qRT‐PCR analysis of lipid metabolism–related genes in MKN‐74 cells treated with LGALS9 conditional medium (upper panel) or recombinant LGALS9 (lower panel). Statistical significance is indicated by asterisks: * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant.

Article Snippet: Recombinant human LGALS9 protein (R&D Systems) was added to the culture medium at a concentration of 150 ng/mL.

Techniques: Expressing, Quantitative RT-PCR, Recombinant, MTT Assay, Cell Culture, Western Blot